Loading...
BioNxt Solutions Inc.
BNXT.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.81
CA$0.07(9.46%)

Over the last four quarters, BioNxt Solutions Inc.'s revenue moved from $19589.00 in Q4 2023 to $17098.00 in Q3 2024. Operating income in Q3 2024 was -$1.22M, with a strong operating margin of -7110%. Despite fluctuations in R&D and SG&A expenses, EBITDA for BioNxt Solutions Inc. remained robust at -$1.19M, reflecting operational efficiency. Net income dropped to -$1.47M, with an EPS of -$0.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan